Clinical trials: Gefitinib, completed
Carcinoma, Non-Small-Cell Lung
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
The primary objective of this trial is to determine the maximum tolerated dose (MTD) and recommended Phase II doses for the combination of BIBW 2992 and cetuximab in patients with non-small cell lung cancer and acquired…
- Trial name
- NCT01090011
- Testing
- Cetuximab, BIBW 2992
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 171 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00083057
- Testing
- gefitinib, paclitaxel, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to learn whether HKI-272 is safe and effective in treating non-small cell lung cancer.
- Trial name
- NCT00266877
- Testing
- HKI-272
- Where
- 19 sites in United States, France and 3 more
- Volunteers
- 172 people
- Sponsor
- Puma Biotechnology, Inc.
Lung Cancer
Gefitinib Usage and Outcomes in Routine Treatment
The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population
- Trial name
- NCT01818947
- Where
- 12 sites in United Kingdom
- Volunteers
- 157 people
- Sponsor
- AstraZeneca
Cancer of Head and Neck
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
· To evaluate the disease free survival rate at 2 years of patients with advanced head and neck carcinoma treated with ZD1839 250 mg administered once daily in combination with cisplatin and a standard course of radiotherapy.
- Trial name
- NCT00242749
- Testing
- Gefitinib, Cisplatin and Radiotherapy
- Where
- 4 sites in Spain
- Volunteers
- 47 people
- Sponsor
- AstraZeneca
Prostate Cancer
Open Label Trial to Assess Iressa in Prostate Cancer Patients
A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels
- Trial name
- NCT00635856
- Testing
- Gefitinib
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Healthy
Bioequivalence Study of Gefitinib Tablets Under Fed Conditions
The study design is an Open-Label，Randomized, Single-Dose, 2-way Crossover Bioequivalence Study. During each session, the subjects will be administered a single dose of 250mg Gefitinib Tablet (one Gefitinib Tablet 250mg of Hunan…
- Trial name
- NCT03050177
- Testing
- Gefitinib Tablet 250mg of Hunan Kelun, Iressa® Tablet 250mg of AZN
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Hunan Kelun Pharmaceutical Co., Ltd.
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00014170
- Testing
- gefitinib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Male Breast Cancer, Recurrent Breast Cancer
Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer
This phase II trial is studying how well giving trastuzumab together with gefitinib works in treating patients with HER2-positive breast cancer.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00024154
- Testing
- trastuzumab, gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
This randomized phase II trial is studying how well giving gefitinib together with anastrozole works compared to giving gefitinib together with fulvestrant in treating postmenopausal women with recurrent or metastatic breast…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00057941
- Testing
- anastrozole, gefitinib, fulvestrant
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand
The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.
- Trial name
- NCT01130961
- Where
- Thailand
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Breast Neoplasms
Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study
This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.
- Trial name
- NCT00229697
- Testing
- Gefitinib, Tamoxifen
- Where
- 55 sites in United States, Argentina and 10 more
- Volunteers
- 317 people
- Sponsor
- AstraZeneca
Locally Advanced Prostate Cancer
Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer
The purpose of this study is to determine if the addition of ZD1839 Iressa™ to standard treatment with Casodex® (bicalutamide) for locally advanced prostate cancer can detect a difference in the rate of decrease of prostate…
- Trial name
- NCT00319787
- Testing
- Iressa
- Where
- 3 sites in Norway
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Breast Cancer
Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer
The aim of the study is to estimate the effect of preoperative gefitinib on the complete pathological response rate in primary estrogen receptor negative breast cancer at the time of surgery.
- Trial name
- NCT00239343
- Testing
- gefitinib
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 160 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Carcinoma
SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients
The purpose of this study is to evaluate ORR (Objective Response Rate) of gefitinib as a second-line therapy for NSCLC patients based on RECIST (Response Evaluation Criteria in Solid Tumors Group) and check up ORR difference by…
- Trial name
- SELINE (NCT00608868)
- Testing
- Gefitinib
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- AstraZeneca
Neoplasms, Squamous Cell
IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms…
- Trial name
- NCT00229723
- Testing
- gefitinib (Iressa), cisplatin, radiotherapy
- Where
- 25 sites in United States, Belgium and 6 more
- Volunteers
- 224 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations
This study is a prospective trial of Alimta (pemetrexed) versus IRESSA (gefitinib) among epidermal growth factor receptor wild-type Non-Small Cell Lung Cancer (NSCLC) patients in a 2nd line setting.
- Trial name
- NCT00891579
- Testing
- Pemetrexed (Alimta), Gefitinib (IRESSA)
- Where
- 7 sites in China
- Volunteers
- 161 people
- Sponsor
- Chinese Society of Lung Cancer
Esophageal Cancer
Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00258323
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Case Comprehensive Cancer Center
Colorectal Cancer
A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma
The primary objective of this study is to compare the activity of raltitrexed and ZD1839 versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by estimating progression free survival (PFS) in…
- Trial name
- NCT00234429
- Testing
- Gefitinib, raltitrexed
- Where
- 9 sites in Spain
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
NSCLC
A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer
Fruquintinib in combination with Gefitinib as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring activating EGFR mutations : a single-arm, multicenter, phase II study
- Trial name
- NCT02976116
- Testing
- Fruquintinib, Gefitinib
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Hutchison Medipharma Limited